Genzyme General, Pharming, Synpac Inc. deal

Synpac granted GENZ exclusive worldwide rights to develop and commercialize Synpac's Pompase recombinant human alpha-glucosidase as an enzyme replacement therapy for Pompe's disease. In addition, GENZ and its partner PHAR plan to share funding of Pompase development. Synpac will receive $19.5 million from GENZ, and PHAR will issue a convertible note to GENZ for $10 million. ...